19:48 , Feb 1, 2019 |  BC Week In Review  |  Company News

Aduro reducing headcount by 37%, focusing on STING

Aduro Biotech Inc. (NASDAQ:ADRO) said it will reduce headcount by 37% to focus on discovery and development of compounds against STING, via its deals with Novartis AG (NYSE:NVS; SIX:NOVN) and Eli Lilly and Co. (NYSE:LLY),...
07:00 , Oct 5, 2015 |  BC Week In Review  |  Company News

BioNovion, Aduro Biotech deal

Aduro will also gain BioNovion’s antibody production technology, which is based on the clonal expansion of cultured B cells isolated from the spleen or lymph nodes of immunized mice, and five bispecific antibodies against undisclosed...